secwatch.observer — SEC 8-K summary
======================================

Issuer:     PDS Biotechnology Corp (PDSB)
CIK:        0001472091
Form:       8-K
Filed at:   2026-05-13T11:05:28+00:00
Accession:  0001140361-26-020934
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PDS Biotech Q1 net loss $7.3M ($0.13/sh); VERSATILE-003 amended with PFS endpoint
--------------------------------------------------------------------------------

- Net loss $7.3M ($0.13 per share) vs $8.5M ($0.21) YoY; revenue not reported.
- R&D expenses $3.5M, down from $5.8M; cash $21.7M at March 31.
- VERSATILE-003 Phase 3 amended to add PFS as interim primary endpoint, reducing enrollment; patients already enrolled continue.
- PDS01ADC mCRC trial: 77.8% ORR and ~85% 24-month survival; mCRPC trial: median PFS 9.6 months.
- New US and Japan patents granted for PDS0101, extending market protection into 2040s.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472091/000114036126020934/0001140361-26-020934-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472091/000114036126020934/ef20073195_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-020934

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer